A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS.

Trial Profile

A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2016

At a glance

  • Drugs Bortezomib (Primary) ; Aspirin; Enoxaparin sodium; Melphalan; Prednisone; Thalidomide; Warfarin
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 May 2016 Status changed from active, no longer recruiting to completed.
    • 03 Jun 2014 Results from a pooled analysis of this and another phase III trial (NCT00551928) comparing continuous versus fixed duration of therapy was presented at 50th Annual Meeting of American Society of Clinical Oncology.
    • 10 Dec 2012 Results were presented at the 54th Annual Meeting and Exposition of the American Society of Hematology (ASH), and were reported in a Millennium media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top